BWA
AXSM icon

Basecamp Wealth Advisors’s Axsome Therapeutics AXSM Stock Holding History

Basecamp Wealth Advisors’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.38K Hold
22
– – ﹤0.01% 1161
2026
Q1 		$3.72K Buy
22
+16
+267% +$2.76K ﹤0.01% 1245
2025
Q4 		$1.1K Buy
+6
New +$838 ﹤0.01% 1474

Other funds holding AXSM

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Basecamp Wealth Advisors's AXSM Position: Q2 2026 in Review

Basecamp Wealth Advisors held its Axsome Therapeutics (AXSM) position steady in Q2 2026 at 22 shares worth $5.38K. The position accounts for ﹤0.01% of the portfolio, ranked #1161.

Basecamp Wealth Advisors first reported a position in AXSM in Q4 2025 and has held it in 3 quarters since. 504 funds tracked by Wall St. Rank hold AXSM as of Q2 2026.

  • Basecamp Wealth Advisors held 22 shares of Axsome Therapeutics worth $5.38K as of Q2 2026.
  • Basecamp Wealth Advisors left its Axsome Therapeutics share count unchanged in Q2 2026.
  • Axsome Therapeutics made up ﹤0.01% of Basecamp Wealth Advisors's portfolio in Q2 2026, its #1161 holding.
  • Basecamp Wealth Advisors first reported a position in Axsome Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 504 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q2 2026.

Based on Basecamp Wealth Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.